Qrons Overview
Qrons is a biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. Its approach seeks to marshal and leverage the remarkable advances made in the fields of artificial intelligence (AI), machine learning (ML), molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. The company has two product candidates for treating traumatic brain injuries, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material. QS100 is an injury-specific, 3D-printable, implantable MSC-synthetic hydrogel for treating penetrating brain injuries. QS200 is an injectable MSC-synthetic hydrogel for the treatment of concussions. The company conducts its research in Israel under service agreements with Ariel University and has an ongoing sponsored research agreement with Dartmouth College.
Latest News
growth-positive
Qrons / First Person Provides Shareholder Update and Strategic Overview
First Person, a cognitive performance company, has successfully merged with QRONS, Inc. and is focusing on science-backed products in supplements and functional beverages. The company is in the process of completing post-merger audits and SEC filings. Due to the complexity of the acquisition, there may be a temporary transition from the OTCQB to the OTC Expert market. However, this is expected to be a short-term administrative step, and the company plans to requalify for the OTCQB market tier promptly. First Person is also preparing for a Reg A capital raise and plans to launch a new alcohol- and THC-free social tonic this year.
Acquired-byProduct Stage
growth-positive
First Person and Qrons Complete Merger, Creating a Publicly Traded Leader in Cognitive Wellness & Functional Beverages
First Person, a company focused on cognitive wellness and functional beverages, has successfully merged with Qrons Inc., creating a publicly traded entity. This merger positions First Person to accelerate growth, expand product distribution, and innovate in the cognitive health and functional wellness markets. The company plans to scale its cognitive wellness platform, expand its brand footprint, and drive innovation through proprietary ingredients and biotechnology partnerships. The merger is seen as a strategic move to enhance market reach and introduce new products, such as alcohol-free social tonics, to meet the growing demand for cognitive health solutions. The combined company will operate under the First Person brand, aiming to deliver long-term value to consumers and shareholders.
Acquired-by
growth-positive
First Person and Qrons Complete Merger, Creating a Publicly Traded Leader in Cognitive Wellness & Functional Beverages
First Person, a cognitive wellness and functional beverage innovator, has successfully merged with Qrons Inc., creating a publicly traded company focused on cognitive health and functional wellness markets. This merger positions First Person to accelerate growth, expand product distribution, and innovate in cognitive supplements and alcohol-free social tonics. The company aims to scale its cognitive wellness platform, expand its market reach, and drive innovation through proprietary ingredients and biotechnology partnerships. The merger is seen as a strategic move to enhance mental clarity, stress relief, and social experiences, aligning with consumer priorities. First Persons mission-driven approach and ability to execute and scale position it for long-term growth.
Acquired-by
growth-positive
First Person Ltd. signed a letter of intent to acquire Qrons Inc. in a reverse merger transaction.
First Person Ltd. has signed a letter of intent to acquire Qrons Inc. in a reverse merger transaction. The merger agreement involves the issuance of 8,000 shares of Qrons Series B Convertible Preferred Stock to First Persons shareholders. Post-merger, First Persons stockholders will hold 80.51% of Qrons common stock, while Qrons holders will retain 14.5% with anti-dilution protection. Venture Group LLC will hold 4.99% of restricted common shares. The merger is contingent on several conditions, including First Person obtaining $250,000 in funding commitments. The transaction is expected to complete between October 16, 2024, and January 20, 2025.
Acquired-by
growth-positive
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program
Qrons Inc. has announced that Professor Shiri Navon-Venezia will join its Scientific Advisory Board. Professor Venezia is a renowned microbiologist and an expert in the field of antibiotic resistance. Her appointment is expected to significantly contribute to Qrons research program, particularly in the development of treatments for antibiotic-resistant bacterial infections, including Sepsis. Qrons is a biotechnology company focused on combating neuronal and infectious diseases, with a special emphasis on antibiotic-resistant bacteria.
Management ChangesExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $500K |
| Last funding | $500K |
| Stage | Public |
| Rounds | 2 |
| Investors | 0 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | qrons.com/ |
Locations
Ramat HaGolan St 65, Ari'el
28-10 Jackson Ave #26n, Long Island City, NY 11101, USA
Photos & Videos
1 item(s)
Qrons Business
Business models
B2B
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticalsBiotechnologyCore Technology
Artificial IntelligenceMachine LearningBiologicalsCellsTags (12)
medical-technologiesbiotechnologyalzheimers-diseasestem-cellsacademiaparkinsonregenerative-medicineneurology3d-technologyhospitalsartificial-intelligencemachine-learningQrons Financials
$500K
Total funding
—
Capital raised
$500K
Last funding
Public
Funding stage
2
Total rounds
0
Investors
Public Offering / Exit
ReverseMergerEvent
Feb 2025
Undisclosed
POEvent
Feb 2018
Undisclosed
POEvent
Aug 2017
Undisclosed
Qrons Lifecycle
All Events
ReverseMergerEvent
Feb 2025
Undisclosed
POEvent
Feb 2018
Undisclosed
POEvent
Aug 2017
Undisclosed
Qrons News
31 articles
growth-positive
Qrons / First Person Provides Shareholder Update and Strategic Overview
First Person, a cognitive performance company, has successfully merged with QRONS, Inc. and is focusing on science-backed products in supplements and functional beverages. The company is in the process of completing post-merger audits and SEC filings. Due to the complexity of the acquisition, there may be a temporary transition from the OTCQB to the OTC Expert market. However, this is expected to be a short-term administrative step, and the company plans to requalify for the OTCQB market tier promptly. First Person is also preparing for a Reg A capital raise and plans to launch a new alcohol- and THC-free social tonic this year.
Acquired-byProduct Stage
growth-positive
First Person and Qrons Complete Merger, Creating a Publicly Traded Leader in Cognitive Wellness & Functional Beverages
First Person, a company focused on cognitive wellness and functional beverages, has successfully merged with Qrons Inc., creating a publicly traded entity. This merger positions First Person to accelerate growth, expand product distribution, and innovate in the cognitive health and functional wellness markets. The company plans to scale its cognitive wellness platform, expand its brand footprint, and drive innovation through proprietary ingredients and biotechnology partnerships. The merger is seen as a strategic move to enhance market reach and introduce new products, such as alcohol-free social tonics, to meet the growing demand for cognitive health solutions. The combined company will operate under the First Person brand, aiming to deliver long-term value to consumers and shareholders.
Acquired-by
growth-positive
First Person and Qrons Complete Merger, Creating a Publicly Traded Leader in Cognitive Wellness & Functional Beverages
First Person, a cognitive wellness and functional beverage innovator, has successfully merged with Qrons Inc., creating a publicly traded company focused on cognitive health and functional wellness markets. This merger positions First Person to accelerate growth, expand product distribution, and innovate in cognitive supplements and alcohol-free social tonics. The company aims to scale its cognitive wellness platform, expand its market reach, and drive innovation through proprietary ingredients and biotechnology partnerships. The merger is seen as a strategic move to enhance mental clarity, stress relief, and social experiences, aligning with consumer priorities. First Persons mission-driven approach and ability to execute and scale position it for long-term growth.
Acquired-by
growth-positive
First Person Ltd. signed a letter of intent to acquire Qrons Inc. in a reverse merger transaction.
First Person Ltd. has signed a letter of intent to acquire Qrons Inc. in a reverse merger transaction. The merger agreement involves the issuance of 8,000 shares of Qrons Series B Convertible Preferred Stock to First Persons shareholders. Post-merger, First Persons stockholders will hold 80.51% of Qrons common stock, while Qrons holders will retain 14.5% with anti-dilution protection. Venture Group LLC will hold 4.99% of restricted common shares. The merger is contingent on several conditions, including First Person obtaining $250,000 in funding commitments. The transaction is expected to complete between October 16, 2024, and January 20, 2025.
Acquired-by
growth-positive
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program
Qrons Inc. has announced that Professor Shiri Navon-Venezia will join its Scientific Advisory Board. Professor Venezia is a renowned microbiologist and an expert in the field of antibiotic resistance. Her appointment is expected to significantly contribute to Qrons research program, particularly in the development of treatments for antibiotic-resistant bacterial infections, including Sepsis. Qrons is a biotechnology company focused on combating neuronal and infectious diseases, with a special emphasis on antibiotic-resistant bacteria.
Management ChangesExpand
growth-positive
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Biotechnology company Qrons Inc. has launched an updated website to provide investors and the public with an overview of the companys work in combating infectious diseases and sepsis, particularly those caused by antibiotic-resistant bacteria. The company also focuses on combating traumatic brain injuries and other neuronal diseases. The new website will also feature investor relation packages to help the public understand Qrons unique role in addressing global health needs. The company is based in New York City, with research centered in Israel.
CustomersInvestment
growth-positive
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
Qrons Inc., a biotechnology company, has announced the filing of a United States Provisional Patent Application for Tellurium Compositions and Techniques for Use Therewith. The patent relates to the therapeutic effect of certain Tellurium based compounds on antibiotic-resistant bacterial infections, sepsis, and traumatic brain injuries. The filing follows the signing of a License Agreement Term Sheet with Professors Sredni & Albeck of Bar Ilan University in Israel for an exclusive worldwide, perpetual license of their IP in Tellurium based compounds. Qrons aims to combat neuronal and infectious diseases, with a focus on antibiotic-resistant bacteria. The company is taking steps towards commercialization and the advancement of its science.
PartnersInvestment
growth-positive
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries
Qrons Inc. has signed a License Agreement Term Sheet with Professors Benjamin Sredni & Michael Albeck of Bar Ilan University in Israel for an exclusive world-wide, perpetual license of their IP in Tellurium based compounds. The IP will be used in a new research program to experiment and commercialize the therapeutic effect of certain Tellurium based compounds on antibiotic resistance bacterial infections, Sepsis and Traumatic Brain Injuries. The Professors will join Qrons revamped Scientific Advisory Board, be entitled to an earned royalty, substantial options in Qrons and other financial incentives.
PartnersExpand
Qrons files U.S. National Phase of its Patent Application in Furtherance of its QS200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels
Qrons Announces Engagement of Israeli Intellectual Property Law Firm IPK to Develop Roadmap for Its New Product Line
Growth-Positive
Qrons Announces a New Pre-Clinical Research Program to Test the Efficacy of Tellurium Based Compounds, in Combination with its QS200(TM) Product Candidate or Independently, in Treating Diffused Axonal Injuries and Antibiotic Resistant Bacteria and Sepsis
Qrons Inc. has announced a collaboration with scientists at a large public research university in Israel to experiment with Tellurium based compounds in combination with Qrons QS200™ product candidate for the treatment of diffused axonal injuries, which account for approximately 89% of Traumatic Brain Injuries. Preliminary studies suggest that some configurations may have a significant therapeutic effect on antibiotic resistant bacteria infections and Sepsis. Qrons plans to proceed to the next phase of pre-clinical and a limited pilot clinical experimental program, dependent on funding. The company is also in discussions with Ariel University to resume lab work as part of the collaboration.
PartnersExpand
growth-positive
Qrons Extends Sponsored Research Agreement with Dartmouth College
Qrons Inc. has extended its Sponsored Research Agreement with Dartmouth College for an additional year with funding through July 14, 2020. The agreement aims to develop innovative 3D printable, biocompatible advanced materials for the treatment of traumatic brain injuries (TBIs). Qrons has also entered into an Intellectual Property License Agreement with Dartmouth for an exclusive worldwide license of intellectual property related to 3D printable materials. The extension of the agreement demonstrates the working relationship between the two teams and the importance of continuing the research. Qrons is a biotechnology company focused on developing stem cell-based solutions for neuronal injuries, particularly TBIs.
Partners
growth-positive
Qrons Granted Exclusive World-Wide License by Dartmouth College for Intellectual Property Related to 3D Printable Materials in Human and Animal Health
Qrons Inc. has entered into an Intellectual Property License Agreement with Dartmouth College for an exclusive worldwide license of Intellectual Property related to 3D printable materials in the fields of human and animal health. The agreement allows Qrons to develop advanced stem cell-synthetic hydrogel-based solutions for the treatment of traumatic brain injuries. Qrons is using the 3D process covered by the patent entitled Mechanically Interlocked Molecules-based Materials for 3D Printing to create injury-specific 3D printable implants for penetrating brain injuries. The company is also working with Dartmouth on additional research and development of smart hydrogels with 3D printing capability. This partnership and licensing agreement will contribute to Qrons growth in the field of traumatic brain injury treatment.
Partners
growth-positive
Qrons Announces Appointment of Derrick Chambers to Advisory Board
Former NFL player Derrick Chambers has been appointed to the Advisory Board of Qrons Inc., an emerging biotechnology company focused on developing stem cell-based solutions for traumatic brain injuries. Chambers, who is a member of the NFL Players Association and Alumni Association, will contribute his financial literacy expertise and help raise awareness of Qrons potential in treating TBIs. Qrons has two product candidates for treating TBIs, including an implantable stem cell-synthetic hydrogel for penetrating brain injuries and an injectable hydrogel for concussions. The company has partnerships with Ariel Scientific Innovations Ltd. and Dartmouth College for research and development. Qrons aims to combat neuronal injuries and is dedicated to the treatment of TBIs.
PartnersCustomers
growth-positive
Qrons Selects PCG Advisory for Investor Relations and Strategic Communications as it Advances its Product Candidates
Qrons Inc., a biotechnology company developing stem cell-based solutions for traumatic brain injuries, has retained PCG Advisory Inc. for investor relations and capital market advisory services. Qrons has developed two product candidates for the treatment of TBIs and recently appointed a Chief Operating Officer. PCG Advisory will assist Qrons in communicating their advancements to investors. Qrons work is important as there are currently no approved treatment options for traumatic brain injuries. The company is headquartered in New York City and has entered into licensing and research agreements with Ariel Scientific Innovations Ltd. and Dartmouth College. PCG Advisory is a strategic advisory firm specializing in investor and stakeholder relations for emerging growth companies.
Partners
growth-positive
Qrons Announces Upgrade to OTCQB Market
Qrons Inc., a biotechnology company developing stem cell-synthetic hydrogel-based solutions for traumatic brain injuries, has announced that its common stock has begun trading on the OTCQB Venture Market. The company has upgraded from the Pink Market. Qrons believes that the move to OTCQB will provide investor benefits including enhanced reporting standards, greater access to analyst coverage and news services, management certification and more comprehensive compliance requirements. The companys CEO, Jonah Meer, commented that the move will raise the companys visibility within the investment community and increase the liquidity of their common stock.
Public TradingManagement Changes
growth-positive
Qrons Appoints Veteran U.S. Based Biotech Executive Dr. John N. Bonfiglio to Lead IND and Capital Markets Related Activities
Qrons Inc., a biotechnology company developing stem cell-synthetic hydrogel-based solutions for traumatic brain injuries, has appointed John N. Bonfiglio as its Chief Operating Officer. Dr. Bonfiglio will oversee all investigational new drug activities in the United States and assist in expanding the companys U.S. capital market activities. The appointment is part of Qrons strategy to strengthen its U.S. operations and accelerate the regulatory approval process for its product candidates. Qrons aims to develop advanced cell-based solutions for the treatment of traumatic brain injuries, including concussions and penetrating injuries. The company has two product candidates, QS100™ and QS200™, which integrate proprietary modified mesenchymal stem cells and synthetic material. Qrons has also entered into license and research funding agreements with Ariel Scientific Innovations Ltd. and Dartmouth College.
Management Changes
growth-positive
Qrons Appoints Dr. Motti Ratmansky as Special Advisor for IND & Clinical Trial Preparations
Qrons Inc., a biotechnology company focused on developing stem cell-synthetic hydrogel-based solutions for neuronal injuries, has announced the appointment of Dr. Motti Ratmansky as Special Advisor to the Company for IND & Clinical Trials. Dr. Ratmansky, a member of Qrons’ Scientific Advisory Board, will take a more active role to assist the company in preparing for its IND (Investigational New Drug) filing. The company is also considering the addition of US-based individuals to its operation.
Management ChangesExpand
growth-positive
Qrons Announces Filing of PCT Patent -- Techniques for Promoting Neuronal Recovery
Qrons Inc., an emerging biotechnology company, has filed a PCT patent application for the treatment of traumatic injury to the central nervous system. The application includes several hundred claims relating to the uses of hydrogels in the treatment of such conditions. If granted, these patents could provide protection for Qrons technology for 20 years. The company believes that this filing is a significant step in protecting their innovative TBI therapy and preparing for clinical trials. The patent application originated from provisional applications filed with the USPTO. Qrons Inc. is developing advanced cell-based solutions to combat neuronal injuries, with a focus on traumatic brain injuries and concussion.
Investment
growth-positive
Qrons Retains Investment Banking Firm Network1 Financial Securities Inc.
Qrons Inc. has retained investment banking firm Network1 Securities Inc. as its Capital Markets Advisory and Investment Banking firm. Network1 will act as Qrons Advisor and Banker in connection with the overall management of its recent OTC listing, including the functions of capital raising, investor management, and guidance and support for a possible uplisting to a major exchange when appropriate. Qrons Inc. is an emerging biotechnology company developing advanced cell-based solutions to combat neuronal injuries, with a focus on traumatic brain injuries and concussion. The company has two product candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material. Qrons Inc. is headquartered in Miami, Florida.
InvestmentPublic Trading
growth-positive
Qrons Completes Successful In-Vivo Experiment with its QS100 Candidate Product for Treating Penetrating Brain Injuries in an Animal Model
Qrons Inc., a preclinical biotechnology company, has reached a milestone in the development of its two candidate products for treating traumatic brain injuries (TBIs). The company has developed QS100™ for treating penetrating brain injuries and QS200™ for treating concussions and other diffused axonal injuries. Both products integrate proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material. QS100™ has demonstrated positive results in animal experiments, while QS200™ is near completion of preclinical experiments. The company has filed a second provisional patent application for its techniques for promoting neuronal recovery. Qrons Inc. is focused on developing advanced cell-based solutions to combat neuronal injuries and has the potential to treat a wide range of neurodegenerative diseases.
InvestmentPartners
growth-positive
Qrons Extends Services Agreement with Ariel University for Additional Year
Qrons Inc. has renewed its Services Agreement with Ariel University for an additional year. This will allow Qrons to carry out the development of its modified mesenchymal stem cells (MSCs) lines and supply models to aid in the treatment of traumatic brain injuries (TBIs). The renewal of the agreement is seen as a growth-positive move for the company. Qrons aims to develop its first candidate product to treat TBIs and plans to enter into clinical trials after delivery. The company believes its solution stands out in addressing the unmet medical need of TBI patients. The renewal of the agreement with Ariel University will support Qrons in achieving its goals.
Partners
growth-positive
Qrons Enters into Placenta Sourcing Agreement under the Declaration of Helsinki
Qrons Inc. has entered into an agreement with Meir Hospital in Israel to obtain a reliable source of human placentas for the development of its proprietary epigenetic modification system. The agreement will accelerate the companys development of manufacturing procedures concerning MSCs extraction, modification, and on-site hydrogel integration. Qrons Inc. aims to produce its first prototype product in the second quarter of 2019, followed by preparatory steps for clinical trials. The company is a preclinical stage biotechnology company focused on developing advanced cell-based solutions to combat neuronal injuries, particularly traumatic brain injuries.
PartnersInvestment
growth-positive
Qrons and Dartmouth College Enter into One Year Sponsored Research Agreement
Qrons Inc. has signed a one-year Sponsored Research Agreement with Dartmouth College to support and fund research on 3D printable, bio-compatible advanced materials and stem cell delivery techniques for the treatment of traumatic brain injuries (TBIs). The agreement allows Qrons to negotiate exclusive licenses for intellectual property developed during the research. Professor Chenfeng Ke of Dartmouth will be the Principal Investigator for the research. Qrons is a preclinical biotechnology company focused on developing advanced cell-based solutions for neuronal injuries. The company is headquartered in Miami, Florida. The agreement with Dartmouth demonstrates the strong working relationship between the two parties and their commitment to finding a solution for TBI.
Partners
growth-positive
Qrons Inc. Engages American Capital Ventures for Investor Relations Services
Qrons Inc., a preclinical biotechnology company, has engaged American Capital Ventures to provide investor relations services. The company is developing advanced cell-based solutions to combat neurological injuries, with a focus on traumatic brain injuries. Qrons Inc. has secured a license from a prominent Israeli University and is working with Dartmouth College on a research study. The company aims to develop innovative 3D printable materials and stem cell delivery techniques to treat TBI. Qrons Inc. is in the process of negotiating a worldwide, royalty-bearing, exclusive license for the 3D printable materials. The engagement of American Capital Ventures is expected to help Qrons Inc. strategically present the company to the investment community.
Investment
growth-positive
Professor Chenfeng Ke of Dartmouth College Joins Qrons Scientific Advisory Board
Qrons Inc. has announced that Chenfeng Ke, Assistant Professor of Chemistry at Dartmouth College, has joined its Scientific Advisory Board. The company has been conducting research with Professor Ke to develop innovative 3D printable, biocompatible advanced materials as a component of its stem cell TBI treatment. Qrons is negotiating with Dartmouth for a worldwide, exclusive license agreement for the intellectual property related to 3D printable materials in the field of human and animal health. The companys co-founders and Head of Research and Development recently met with the heads of various departments at Dartmouth to discuss their collaborative relationship. Qrons is a preclinical biotechnology company focused on developing cell-based solutions to combat neuronal injuries, particularly traumatic brain injuries.
Partners
growth-positive
Qrons Exercises Dartmouth Option
Qrons Inc. is exercising its option to enter into negotiations with Dartmouth College for a worldwide, exclusive license agreement for 3D printable materials in the field of human and animal health. The company is satisfied with the initial evaluation and research results and plans to finalize the license terms. Qrons co-Founders and head of research and development are scheduled to visit Dartmouth in April for further research and business matters. Qrons is a preclinical biotechnology company focused on developing advanced cell-based solutions to combat neuronal injuries, particularly traumatic brain injuries.
Partners
growth-positive
Qrons Raises Funds to Further Its Goals, Expands Advisory Board
Qrons Inc. has sold 312,500 shares of its common stock and raised $500,000 in a private placement offering. The proceeds will be used for research and general corporate purposes. Mr. Pavel Hilman, Chairman of HIG Capital AG, has made the investment and will join Qrons Advisory Board as a business advisor. Qrons is a preclinical biotechnology company focused on developing cell-based solutions for traumatic brain injuries. The company recently presented at the National Investment Banking Association conference. Qrons has also entered into license agreements with Ariel University R&D Co., Ltd. and Dartmouth College for the development of its products.
Investment
growth-positive
Qrons Announces Signing of Option Agreement with Dartmouth College
Qrons Inc. has signed an Option Agreement with Dartmouth College to develop 3D printable, biocompatible materials and stem cell delivery techniques for the treatment of traumatic brain injuries (TBIs). Qrons will have a one-year exclusive option to negotiate a worldwide, royalty-bearing, exclusive license with Dartmouth for the materials. The agreement also includes financing the prosecution of patents by Dartmouth to protect the intellectual property. Qrons and Dartmouth will continue their ongoing research and evaluation of the materials through joint studies. The Option Agreement provides for the payment of initial and annual license fees and royalty payments based on Qrons product sales. Qrons is a preclinical biotechnology company focused on developing advanced cell-based solutions for neuronal injuries.
Partners
growth-positive
Qrons Inc. Announces Launch of New Website Website Offers Visitors Insight Into the Company's Innovative Multi-Disciplinary Approach to Traumatic Brain Injuries
Qrons Inc., a preclinical biotechnology company, has announced the launch of its fully featured website. The website provides comprehensive information about the companys innovative approach to treating traumatic brain injuries. It offers a clean design, functionality, and rich content. The website aims to inform customers, investors, partners, and media about the companys mission and growth. Traumatic brain injuries are a significant cause of death and medical costs in the US. Qrons expects to regularly update the website with news and information. The company is developing advanced cell-based solutions for neuronal injuries and has entered into a license and research funding agreement with Ariel University. Qrons is also conducting a research study with Dartmouth College. The website launch is expected to have a positive impact on the companys growth.
Customers
growth-positive
BioLabMart Inc. Announces Company Name Change to Qrons Inc.
BioLabMart Inc. has changed its name to Qrons Inc. to better reflect its focus on neuro-degenerative diseases and neuronal injuries. The company is developing a novel stem cell system to repair and regenerate neuronal damage, with a preliminary focus on traumatic brain injury. Qrons Inc. has entered into a license and research funding agreement with Ariel University R&D Co., Ltd. to further research cell treatment for neuronal tissue regeneration and repair. The companys common stock now trades under the ticker symbol QRON on the OTC PINK market. Qrons Inc. is also working on making its shares DTC eligible and developing a new website at www.qrons.com.
Management Changes
Qrons Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 4 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
Qrons Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 87/100 |
| Missing | founding month, funding rounds, markets, not claimed |
| BI Verification | Yotam Maman |
| Crunchbase | qrons |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-06-16T00:00:00.000Z |
| Created | 2021-01-26T00:00:00.000Z |
| Status detail | Public on OTC on Aug, 2017; |